|
Study (year) | Outcome | Infarct volume | Treg depletion | Treg adoption | Major findings |
|
Liesz et al. (2009) [55] | Protective | <30 mm3 | Anti-CD25 mAb | None | Larger infarcts and worse neurological function in depletion group on day 7, but not day 1 or 3 |
None | Total CD4+ T cells, Tregs or CD4+CD25− T cells to RAG2−/− mice; /mouse; 7 days before MCAO | Larger infarcts in CD4+CD25− group on day 7 |
|
Ren et al. (2011) [60] | Neutral | ~50 mm3 | DEREG mouse (DT before MCAO) | None | No significant difference associated with depletion within 4 days after MCAO |
|
Li et al. (2012) [51] | Protective | 20–60 mm3 | None | Tregs to wide type; /mouse; the 2nd, 6th, and 24th hours after reperfusion | Reduced infarcts and better neurological function in adoption group out to day 28 |
Anti-CD25 mAb | Tregs to wide type; /mouse; the 2nd, 6th and 24th hours after reperfusion |
|
Stubbe et al. (2013) [52] | Neutral | ~40 mm3 | Anti-CD25 mAb | None | No significant difference associated with depletion |
|
Kleinschnitz et al. (2013) [50]
| Deleterious | 60–90 mm3 | DEREG mouse (DT before MCAO) | | Smaller infarcts and better neurological function in depletion group on days 1 and 4; no secondary infarct growth associated with depletion by day 7 |
5–10 mm3 | DEREG mouse (DT after MCAO) | | No secondary infarct growth associated with depletion by day 7 |
5–10 mm3 | DEREG mouse (DT before MCAO) | CD4+CD25+Tregs or CD4+CD25− T cells or CD4+CD25+FoxP3+ Tregs or CD4+CD25− FoxP3− T cells to RAG2−/− mice; /mouse; 1 day before MCAO | Larger infarcts in all 4 adoption groups than Rag−/− group; no difference between any adoption group and Rag+/+ group |
|
Gu et al. (2012) [61] | Neutral | | | Ebi3 KO | No significant difference associated with depletion within 2 days after MCAO |
|